Jan 7 (Reuters) - The U.S. Food and Drug Administration said on Friday it shortened the stipulated time between the primary series of the Moderna COVID-19 vaccine and a booster dose by a month to at least five months for people aged 18 or above. (Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli)
U.S. FDA cuts gap for Moderna COVID-19 booster dose to five months
![Reuters logo](/images/reuters.jpg)